Pathogenesis of lupus nephritis: An update

Nephrology

Volumn 10, Issue 2, 2005, Pages 174-179

  Tang, Sydney ^a   Lui, Sing Leung ^a   Lai, Kar Neng ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Apoptosis; Autoantibody; Complement; Lupus nephritis; Nitric oxide; Nucleosome; Pathogenesis; Superoxide

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; AUTOANTIBODY; EPITOPE; MERCAPTAMINE; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; APOPTOSIS; AUTOIMMUNE DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; NUCLEOSOME; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ANIMALS; APOPTOSIS; AUTOANTIBODIES; HUMANS; LUPUS NEPHRITIS; SUPEROXIDES;

EID: 20144375468     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00392.x     Document Type: Review

References (52)

1. Holborow EJ, Weir DM, Johnson GD. A serum factor in lupus erythematosus with affinity for tissue nuclei. Br. Med. J. 1957; 13: 732-4.
2. Hahn BH. Antibodies to DNA. N. Engl. J. Med. 1998; 338: 1359-68.
3. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus. Association of high avidity antinative DNA antibody with glomerulonephritis. J. Clin. Invest. 1977; 59: 90-96.
4. Bootsma H, Spronk P, Derksen R et al. Prevention of relapses in systemic lupus erythematosus. Lancet 1995; 345: 1595-9.
5. Diamond B, Katz JB, Paul E, Aranow C, Lustgarten D, Scharff MD. The role of somatic mutation in the pathogenic anti-DNA response. Annu. Rev. Immunol. 1992; 10: 731-57.
6. Fournie GJ. Circulating DNA and lupus nephritis. Kidney Int. 1988; 33: 487-97.
7. Rekvig OP, Kalaaji M, Nossent H. Anti-DNA antibody subpopulations and lupus nephritis. Autoimmun. Rev. 2004; 3: 1-6.
8. Chan TM, Yu PM, Tsang KL, Cheng IK. Endothelial cell binding by human polyclonal anti-DNA antibodies: Relationship to disease activity and endothelial functional alterations. Clin. Exp. Immunol. 1995; 100: 506-13.
9. Chan TM, Cheng IK. Identification of endothelial cell membrane proteins that bind anti-DNA antibodies from patients with systemic lupus erythematosus by direct or indirect mechanisms. J. Autoimmun. 1997; 10: 433-9.
10. Chan TM, Leung JK, Ho SK, Yung S. Mesangial cell-binding anti-DNA antibodies in patients with systemic lupus erythematosus. J. Am. Soc. Nephrol. 2002; 13: 1219-29.
11. Madaio MP, Yanase K. Cellular penetration and nuclear localization of anti-DNA antibodies: Mechanisms, consequences, implications and applications. J. Autoimmun. 1998; 11: 535-8.
12. Alarcon-Segovia D, Ruiz-Arguelles A, Llorente L. Broken dogma: Penetration of autoantibodies into living cells. Immunol. Today 1996; 17: 163-4.
13. Madaio MP, Fabbi M, Tiso M, Daga A, Puccetti A. Spontaneously produced anti-DNA/DNase I autoantibodies modulate nuclear apoptosis in living cells. Eur. J. Immunol. 1996; 26: 3035-41.
14. Hsieh SC, Sun KH, Tsai CY et al. Monoclonal anti-double stranded DNA antibody is a leucocyte-binding protein to up-regulate interleukin-8 gene expression and elicit apoptosis of normal human polymorphonuclear neutrophils. Rheumatology (Oxford) 2001; 40: 851-8.
15. Kubota T, Watanabe N, Kanai Y, Stollar BD. Enhancement of oxidative cleavage of DNA by the binding sites of two anti-double-stranded DNA antibodies. J. Biol. Chem. 1996; 271: 6555-61.
16. Lai KN, Leung JC, Lai KB, Lai FM, Wong KC. Increased release of von Willebrand factor antigen from endothelial cells by anti-DNA autoantibodies. Ann. Rheum. Dis. 1996; 55: 57-62.
17. Lai KN, Leung JC, Lai KB, Wong KC, Lai CK. Upregulation of adhesion molecule expression on endothelial cells by anti-DNA autoantibodies in systemic lupus erythematosus. Clin. Immunol. Immunopathol. 1996; 81: 229-38.
18. Lai KN, Leung JC, Lai KB, Lai CK. Effect of anti-DNA autoantibodies on the gene expression of interleukin 8, transforming growth factor-beta, and nitric oxide synthase in cultured endothelial cells. Scand. J. Rheumatol. 1997; 26: 461-7.
19. Lai KN, Leung JC, Lai KB, Li PK, Lai CK. Anti-DNA autoantibodies stimulate the release of interleukin-1 and interleukin-6 from endothelial cells. J. Pathol. 1996; 178: 451-7.
20. Sun KH, Yu CL, Tang SJ, Sun GH. Monoclonal anti-double-stranded DNA autoantibody stimulates the expression and release of IL-1beta, 1L-6, IL-8, 1L-10 and TNF-alpha from normal human mononuclear cells involving in the lupus pathogenesis. Immunology 2000; 99: 352-60.
21. Yu CL, Sun KH, Tsai CY, Hsieh SC, Yu HS. Anti-dsDNA antibody up-regulates interleuldn 6, but not cyclo-oxygenase, gene expression in glomerular rnesangial cells: A marker of immune-mediated renal damage? Inflamm. Res. 2001; 50: 12-18.
22. Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum. 1999; 42: 833-43.
23. Berden JH. Lupus nephritis. Kidney Int. 1997; 52: 538-58.
24. Berden JH, Licht R, van Bruggen MC, Tax WJ. Role of nucleosomes for induction and glomerular binding of autoantibodies in lupus nephritis. Curr. Opin. Nephrol. Hypertens. 1999; 8: 299-306.
25. Monestier M. Autoantibodies to nucleosomes and histone-DNA complexes. Methods 1997; 11: 36-43.
26. Tax WJ, Kramers C, van Bruggen MC, Berden JH. Apoptosis, nucleosomes, and nephritis in systemic lupus erythematosus. Kidney Int. 1995; 48: 666-73.
27. Kramers C, Hylkema MN, van Bruggen MCLR et al. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement membrane in vivo. J. Clin. Invest. 1994; 94: 568-77.
28. Casciola-Rosen L, Rosen A. Ultraviolet light-induced keratinocyte apoptosis: a potential mechanism for the induction of skin lesions and autoantibody production in LE. Lupus 1997; 6: 175-80.
29. Cabrespines A, Laderach D, Lebosse C, Bach JF, Koutouzov S. Isolation and characterization of apoptotic nucleosomes, free and complexed with lupus autoantibody generated during hybridoma B-cell apoptosis. J. Autoimmun. 1998; 11: 19-27.
30. Mevorach D, Zhou JL, Song X, Elkon KB. Systemic exposure to irradiated apoptotic cells indices autoantibody production. J. Exp. Med. 1998; 188: 387-92.
31. van Bruggen MC, Walgreen B, Rijke TP et al. Antigen specificity of anti-nuclear antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur. J. Immunol. 1997; 27: 1564-9.
32. van Bruggen MC, Kramers C, Walgreen B et al. Nucleosomes and histones are present in glomeiular deposits in human lupus nephritis. Nephrol. Dial. Transplant. 1997; 12: 57-66.
33. Kamradt T, Mitchison NA. Tolerance and autoimmunity. N. Engl. J. Med. 2001; 344: 655-64.
34. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
35. Grodzicky T, Elkon KB. Apoptosis in rheumatic diseases. Am. J. Med. 2000; 108: 73-82.
36. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-76.
37. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67: 889-99.
38. Tang S, Zhou W, Sheerin NS, Vaughan RW, Sacks SH. Contribution of renal secreted complement C3 to the circulating pool in humans. J. Immunol. 1999; 162: 4336-41.
39. Wang Y, Hu Q, Madri JA, Rollins SA, Chodera A, Matis LA. Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc. Natl. Acad. Sci. U S A 1996; 93: 8563-8.
40. Walport MJ. Complement. Second of two parts. N. Engl. J. Med. 2001; 344: 1140-44.
41. Pickering MC, Botto M, Taylor PR, Lachmann PJ, Walport MJ. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv. Immunol. 2000; 76: 227-324.
42. Robson MG, Cook HT, Botto M et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J. Immunol. 2001; 166: 6820-28.
43. Einav S, Pozdnyakova OO, Ma M, Carroll MC. Complement C4 is protective for lupus disease independent of C3. J. Immunol. 2002; 168: 1036-41.
44. Sekine H, Reilly CM, Molano ID et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J. Immunol. 2001; 166: 6444-51.
45. Mitchell DA, Pickering MC, Warren J et al. C1q deficiency and autoimmunity: The effects of genetic background on disease expression. J. Immunol. 2002; 168: 2538-43.
46. Reilly CM, Farrelly LW, Viti D et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 2002; 61: 839-46.
47. Reilly CM, Oates JC, Cook JA, Morrow JD, Halushka PV, Gilkeson GS. Inhibition of mesangial cell nitric oxide in MRL/lpr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists. J. Immunol. 2000; 164: 1498-504.
48. Chan TM, Li FK, Tang CS et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N. Engl. J. Med. 2000; 343: 1156-62.
49. Yu CC, Yang CW, Wu MS et al. Mycophenolate mofetil reduces renal cortical inducible nitric oxide synthase mRNA expression and diminishes glomerulosclerosis in MRL/lpr mice. J. Lab. Clin. Med. 2001; 138: 69-77.
50. Lui SL, Tsang R, Wong D et al. Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice. Lupus 2002; 11: 411-18.
51. Zou MH, Shi C, Cohen RA. Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. J. Clin. Invest. 2002; 109: 817-26.
52. Suwannaroj S, Lagoo A, Keisler D, McMurray RW. Antioxidants suppress mortality in the female NZB × NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001; 10: 258-65.